Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.

Abstract

GSK2336805 is a hepatitis C virus NS5A inhibitor in clinical development for the treatment of chronic hepatitis C virus infection. This was a single-center, randomized, double-blind, placebo-controlled, two-period crossover study in healthy adults to evaluate the effects of a single 150-mg dose of GSK2336805 on echocardiographic measures of contractility. GSK2336805 had no effect on ejection fraction, and there was no significant correlation between GSK2336805 plasma concentration and ejection fraction. (This study has been registered at Clinicaltrials.gov under registration no. NCT01424540.).

• Authors: D A Wilfret, K K Adkison, L A Jones, Y Lou, J Gan, W Spreen
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 57 Issue 10 Pg. 5141-3 (Oct 2013) ISSN: 1098-6596 [Electronic] United States
• PMID: 23856771 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Carbamates
• GSK2336805
• Valine

Topics

• Adult
• Antiviral Agents (adverse effects, therapeutic use)
• Carbamates (adverse effects, therapeutic use)
• Echocardiography (methods)
• Female
• Hepatitis C, Chronic (drug therapy)
• Humans
• Male
• Middle Aged
• Myocardial Contraction (drug effects)
• Valine (adverse effects, analogs & derivatives, therapeutic use)